Increased risk of toxoplasmic encephalitis in human immunodeficiency virus - Infected patients with pyrimethamine-related rash

Clinical Infectious Diseases

Volumn 24, Issue 3, 1997, Pages 396-402

  Rousseau, Franck ^b   Pueyo, Sophie ^b   Morlat, Philippe ^b   Hafner, Richard ^b   Chène, Geneviève ^b   Leport, Catherine ^a   Luft, Benjamin J ^b   Miro, José ^b   Aubertin, Jean ^b   Salamon, Roger ^b   Vildé, Jean Louis ^a  

^a BICHAT HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PYRIMETHAMINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENCEPHALITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TOXOPLASMA; TOXOPLASMOSIS;

EID: 20644452664     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.3.396     Document Type: Article

References (31)

1. Battegay M, Opravil M, Wūthrich B, Lüthy R. Rash with amoxycillin-clavulanate therapy in HIV-infected patients [letter]. Lancet 1989;2:1100.
2. Carr A, Cooper DA, Penny R. Allergic manifestations of human immuno-deficiency virus (HIV) infection. J Clin Immunol 1991;11:55-64.
3. Coopman SA, Johnson RA, Platt R, Stem RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-4.
4. Dover JS, Johnson RA. Cutaneous manifestations of human immunodeficiency virus infection: part I. Arch Dermatol 1991;127:1383-91.
5. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
6. Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983;2:1109-11.
7. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100:663-71.
8. McNeely MC, Yarchoan R, Broder S, Lawley TJ. Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection. J Am Acad Dermatol 1989;21:1213-7.
9. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991;337:627-30.
10. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau J-C. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992;26: 567-74.
11. Kaufman HE, Caldwell LA. Pharmacological studies of pyrimethamine (Daraprim) in man. AMA Arch Ophthalmol 1959;61:885-90.
12. Cutler TP. Lichen planus caused by pyrimethamine. Clin Exp Dermatol 1980;5:253-6.
13. Costello JM, Becroft DMO. Drug reaction simulating malignant lymphoma: a case due to pyrimethamine. NZ Med J 1977;86:430-2.
14. Craven SA. Photosensitivity to pyrimethamine? [letter]. BMJ 1974;2:556.
15. Bachmeyer C, Gorin I, Deleuze J, Morini J-P, Escande J-P. Pyrimethamine as primary prophylaxis of toxoplasmic encephalitis in patients infected with human immunodeficiency virus: open study [letter]. Clin Infect Dis 1994;18:479-80.
16. Leport C, Chêne G, Morlat P, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. J Infect Dis 1996;173: 91-7.
17. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34: 187-220.
18. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
19. Girard P-M, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993;328:1514-20.
20. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus elindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992;116:33-43.
21. Jacobson MA, Besch CL, Child C, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. J Infect Dis 1994;169:384-94.
22. Fauci AS. Multifactprial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-8.
23. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309: 453-8.
24. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection [NIH conference discussion]. Ann Intern Med 1991;114:678-93.
25. Webster AW, Thompson RA. The ampicillin rash: lymphocyte transformation by ampicillin polymer. Clin Exp Immunol 1974;18:553-64.
26. Roujeau JC. Toxidermies au cours de l'infection à VIH. Presse Med 1994;23:111-2.
27. Koopmans PP, van der Yen AJAM, Vree TB, van der Meer JWM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 1995;9:217-22.
28. Carr A, Swanson C, Penny R, Cooper DA. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993;167:180-5.
29. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993;342:332-7.
30. May T, Beuscart C, Reynes J, Leport C, Canton Ph, LFPMI group. Cutaneous hypersensitivity to sulfamethoxazole-trimethoprim (SMZ-TMP) in HIV-infected patients: a major risk factor for developing toxoplasmic encephalitis (TE)? [abstract no I 177]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1994:169.
31. Fultz PN, Gluckman J-C, Muchmore E, Girard M. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses 1992;8:313-7.